Jubilant Life Sciences shares continued to remain under pressure, hitting 33-month low of Rs 503, down 2 per cent in intra-day trade on the BSE on Wednesday. The stock has fallen 19 per cent in the past nine trading days, after reporting weak March quarter earnings. The stock was quoting at its lowest level since August 29, 2016.
The pharmaceuticals company had reported a net loss of Rs 101 crore in the fourth quarter ended March 31, 2019 (Q4FY19) on account of a one-time loan settlement with International Finance Corporation (IFC). It had posted a consolidated net profit of
The pharmaceuticals company had reported a net loss of Rs 101 crore in the fourth quarter ended March 31, 2019 (Q4FY19) on account of a one-time loan settlement with International Finance Corporation (IFC). It had posted a consolidated net profit of